# MEtformin and Lorcaserin for WeighT Loss in Schizophrenia

> **NCT02796144** · PHASE4 · TERMINATED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 71 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Overweight

## Interventions

- **DRUG:** Lorcaserin
- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02796144
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2020-02-14
- **Final completion:** 2020-02-14
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.
- **Last updated:** 2021-03-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02796144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02796144, "MEtformin and Lorcaserin for WeighT Loss in Schizophrenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02796144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*